AstraZeneca and UCL to collaborate on two immuno-oncology projects
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
The new research collaborations will investigate immune checkpoints – key biochemical pathways that regulate the body’s immune responses.
Although immune checkpoints help to keep the body’s immune response at normal levels by not harming healthy cells, they can also block specialist immune cells from attacking and destroying cancer cells.
Over the last decade, the emergence of checkpoint inhibitor drugs have revolutionised cancer treatment and demonstrated benefit in clinical results for patients with solid tumours.
Meanwhile, the two AstraZeneca/UCL projects will focus on increasing understanding of immune checkpoint mechanisms and how to manipulate them.
The ultimate aim of the projects will to be to aid the development of new immunotherapy approaches.
Read more: http://www.pharmatimes.com/news/astrazeneca_and_ucl_to_collaborate_on_two_immuno-oncology_projects_1362693
The new research collaborations will investigate immune checkpoints – key biochemical pathways that regulate the body’s immune responses.
Although immune checkpoints help to keep the body’s immune response at normal levels by not harming healthy cells, they can also block specialist immune cells from attacking and destroying cancer cells.
Over the last decade, the emergence of checkpoint inhibitor drugs have revolutionised cancer treatment and demonstrated benefit in clinical results for patients with solid tumours.
Meanwhile, the two AstraZeneca/UCL projects will focus on increasing understanding of immune checkpoint mechanisms and how to manipulate them.
The ultimate aim of the projects will to be to aid the development of new immunotherapy approaches.
Read more: http://www.pharmatimes.com/news/astrazeneca_and_ucl_to_collaborate_on_two_immuno-oncology_projects_1362693
